Equillium up on plans to advance drug to late-stage trial after FDA input

Equillium

13/07/2021 13:28

** Biotech co's shares  EQ.O  rise 6.7% to $6.02 premarket
    ** EQ on Monday after market said following a meeting with
the U.S. FDA, it will advance its monoclonal antibody,
itolizumab, into a single Phase 3 pivotal study to support its
marketing application  urn:newsml:reuters.com:*:nGNX5l7Hr6
    ** Co plans to initiate the study in Q4 
    ** Drug intended for treatment of acute graft-versus-host
disease (aGVHD) - a multisystem disorder that is a common
complication of stem cell transplants 
    ** EQ had risen 5.4% YTD, up to the last close

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))